(Z)-3-(acridin-9-ylamino)-2-(5-chloro-1,3-benzoxazol-2-yl)prop-2-enal

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (Z)-3-(acridin-9-ylamino)-2-(5-chloro-1,3-benzoxazol-2-yl)prop-2-enal
• 化学式: C₂₃H₁₄ClN₃O₂
• 分子量: 399.8
• InChiKey: WXMGVBWGXMNBFI-WYMLVPIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NUCLEASE SYSTEMS FOR GENETIC ENGINEERING
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：EP3679137A1

  公开（公告）日：2020-07-15
• MESOPHILIC ARGONAUTE SYSTEMS AND USES THEREOF
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：EP3935165A1

  公开（公告）日：2022-01-12
• INHIBITION OF NF-KB
  申请人：Gudkov Andrei V.

  公开号：US20090099191A1

  公开（公告）日：2009-04-16

  The present invention is generally related to the modulation of cell growth or apoptosis. Compositions for modulating cell growth or apoptosis, methods of use thereof, and methods of identification thereof are described.
• [EN] TREATMENT OF ISCHEMIC EYE DISEASE BY THE SYSTEMATIC PHARMACEUTICAL ACTIVATION OF HYPOXIA INDUCIBLE FACTOR (HIF)<br/>[FR] TRAITEMENT D'UNE MALADIE ISCHÉMIQUE DE L'OEL PAR ACTIVATION PHARMACEUTIQUE SYSTÉMATIQUE D'UN FACTEUR INDUIT PAR L'HYPOXIE (HIF)
  申请人：CLEVELAND CLINIC FOUNDATION

  公开号：WO2009035534A2

  公开（公告）日：2009-03-19

  The present invention consists of a method of treating a subject with an ischemic eye disease associated with the down-regulation of HIF comprising administering to the subject an effective amount of a compound that induces HIF activity and/or induces EPO activity to induce and maintain growth or normal retinal blood vessels in the early stage of the disease.
• [EN] NUCLEASE SYSTEMS FOR GENETIC ENGINEERING<br/>[FR] SYSTÈMES DE NUCLÉASES POUR GÉNIE GÉNÉTIQUE
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2019051278A1

  公开（公告）日：2019-03-14

  Fusion constructs encoding RNase-H-like domain containing compositions are disclosed. Disclosed are also compositions and methods utilizing RNase-H-like domain containing compositions for the treatment of cancer. Also disclosed are the methods of making and using the RNase-H-like domain containing compositions in treating various diseases, conditions, and cancer.